ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022GlobeNewsWire • 04/01/22
ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 MonthsGlobeNewsWire • 03/25/22
ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital ManagementGlobeNewsWire • 03/24/22
ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022GlobeNewsWire • 03/21/22
ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GAGlobeNewsWire • 03/07/22
ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business UpdateGlobeNewsWire • 01/19/22
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SCGlobeNewsWire • 01/18/22
Implied Volatility Surging for ADMA Biologics (ADMA) Stock OptionsZacks Investment Research • 12/10/21
ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of DirectorsGlobeNewsWire • 11/17/21
ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SCGlobeNewsWire • 11/16/21
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/11/21
ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and AccomplishmentsGlobeNewsWire • 11/10/21